1.Study on mechanism of Drynariae Rhizoma in treating osteoporosis with integrative pharmacology perspective.
Yi-Li ZHANG ; Bin TANG ; Jun-Jie JIANG ; Hao SHEN ; Yan-Ming XIE ; Xu WEI
China Journal of Chinese Materia Medica 2018;43(20):4125-4131
Drynariae Rhizoma has great significance in the clinical practice of osteoporosis treatment. Based on the perspective of integrative pharmacology, the study explored the mechanism of action of Drynariae Rhizoma in the treatment of osteoporosis. Six active components in Drynariae Rhizoma were obtained, mainly including glycosides and sterols. Taking the median of 2 times of "node connectivity" as the card value, the core node of the Chinese medicine target disease gene interaction network was selected. Based on this, three topological structural eigenvalues, such as "node connectivity" "node tightness" and "node connectivity" were calculated, thereby screening out four core targets of Drynariae Rhizoma treatment for osteoporosis, including thyroid parathyroid hormone 1 receptor (PTH1R), parathyroid hormone 2 receptor (PTH2R), calcitonin receptor gene (CALCR), and SPTBN1 gene (SPTBN1). Based on the gene ontology database GO and KEGG pathway database, the molecular function, intracellular localization, and biological reactions and pathways of proteins encoded by drug target genes were determined. Combined with enrichment calculation, it is predicted that osteoporosis may play a role in biosynthetic processes, such as circulatory system, nervous system, energy metabolism, prolactin signal pathway, GnRH signaling pathway, neurotrophic factor signaling pathway and other pathway. The conclusion of this study is certain with the existing research results, and the new target and new pathway could also be used as a theoretical basis for the further verification of osteoporosis.
Drugs, Chinese Herbal
;
pharmacology
;
Humans
;
Osteoporosis
;
drug therapy
;
Polypodiaceae
;
chemistry
;
Receptor, Parathyroid Hormone, Type 1
;
metabolism
;
Receptor, Parathyroid Hormone, Type 2
;
metabolism
;
Receptors, Calcitonin
;
metabolism
;
Rhizome
;
chemistry
;
Spectrin
;
metabolism
2.The parathyroid hormone-2 receptor: Current status.
Experimental & Molecular Medicine 1997;29(1):13-17
G-protein coupled receptors form a large superfamily of plasma membrane proteins which serve a variety of signal transduction roles. New receptors continue to be identified. Based on sequence homology the superfamily can currently be divided into three families, the rhodopsin family which includes the vast majority of identified receptors, and the secretin. and metabotropic glutamate receptor families which share a general architecture with each other and the rhodopsin family but no obvious sequence identity. Screening for additional members of the secretin family led to the identification of the parathyroid hormone-2 (PTH2) receptor. Ligand recognition by the PTH2 receptor partially overlaps that of the PTH/parathyroid hormone-related peptide (PTHrP) receptor. This has facilitated structure-function analysis of ligands for these receptors. The physiological role of the PTH2 receptor is under investigation but its distribution suggests that it may be a neurotransmitter receptor and could participate in modulation of a number of organ systems. The relative abundance of PTH2 receptor mRNA in the brain and the inability to detect mRNA encoding PTH, its only currently identified ligand, suggest the existence of another endogenous ligand, for which evidence has recently been obtained.
Brain
;
Cell Membrane
;
GTP-Binding Proteins
;
Humans
;
Ligands
;
Mass Screening
;
Neurotransmitter Agents
;
Parathyroid Hormone
;
Receptor, Parathyroid Hormone, Type 2
;
Receptors, Metabotropic Glutamate
;
Receptors, Neurotransmitter
;
Rhodopsin
;
RNA, Messenger
;
Secretin
;
Sequence Homology
;
Signal Transduction